{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:38:43Z","timestamp":1783460323775,"version":"3.55.0"},"reference-count":37,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DK101941"],"award-info":[{"award-number":["R01-DK101941"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001105"],"award-info":[{"award-number":["UL1TR001105"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Familial partial lipodystrophy, type 2 (FPLD2) or the Dunnigan variety, is a rare, autosomal dominant disorder characterized by selective loss of subcutaneous fat from the extremities and is caused by over 50 heterozygous missense LMNA variants. However, some patients with FPLD2 do not harbor the known pathogenic LMNA variants and there are only limited genotype\u2013phenotype segregation data for a few other variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the genotype\u2013phenotype relationships in 4 families with ultrarare and novel LMNA variants causing FPLD2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical, anthropometric, and laboratory data of affected and unaffected subjects from 4 families with female probands presenting with FPLD2 phenotype were collected retrospectively. The main parameters were clinical phenotype, skinfold thickness, regional body fat by dual-energy X-ray absorptiometry (DXA), metabolic variables, and prevalence of diabetes mellitus and hypertriglyceridemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 2 ultrarare (p.N466D, and p.K515E) and 2 novel (p.R582S, and p.L241P) LMNA heterozygous variants in 4 unrelated FPLD2 families. All adult affected females had thigh skinfold thickness below the 10th percentile of normal and lower extremity fat below the 1st percentile of normal suggesting \u201ctypical\u201d FPLD2. None of our patients had any cardiomyopathy, muscular dystrophy, neuropathy, or any progeroid features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data provide further supporting evidence for the pathogenicity of 2 previously reported ultrarare heterozygous LMNA variants, p.N466D and p.K515E. We also report 2 novel variants, p.R582S and p.L241P, in patients with FPLD2. Thus, our study broadens the spectrum of pathogenic\/likely pathogenic LMNA variants in FPLD2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf279","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:05:30Z","timestamp":1746777930000},"page":"e214-e224","source":"Crossref","is-referenced-by-count":4,"title":["Novel and Ultrarare Heterozygous Missense\n                    <i>LMNA<\/i>\n                    Variants Causing Familial Partial Lipodystrophy"],"prefix":"10.1210","volume":"111","author":[{"family":"Anum","sequence":"first","affiliation":[{"name":"The Section of Nutrition and Metabolic Diseases, Division of Endocrinology, Department of Internal Medicine and the Center for Human Nutrition, UT Southwestern Medical Center , Dallas, TX 75390-8537 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Li","sequence":"additional","affiliation":[{"name":"Peter O\u2019Donnell Jr. School of Public Health, UT Southwestern Medical Center , Dallas, TX 75390-9066 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-6986","authenticated-orcid":false,"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[{"name":"The Section of Nutrition and Metabolic Diseases, Division of Endocrinology, Department of Internal Medicine and the Center for Human Nutrition, UT Southwestern Medical Center , Dallas, TX 75390-8537 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"3","key":"2025121807421028700_dgaf279-B1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng0398-292","article-title":"Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22","volume":"18","author":"Peters","year":"1998","journal-title":"Nat Genet"},{"issue":"1","key":"2025121807421028700_dgaf279-B2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","article-title":"Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy","volume":"9","author":"Cao","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2025121807421028700_dgaf279-B3","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1210\/clinem\/dgad606","article-title":"Deciphering the clinical presentations in LMNA-related lipodystrophy: report of 115 cases and a systematic review","volume":"109","author":"Besci","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025121807421028700_dgaf279-B4","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a\/c gene","volume":"86","author":"Garg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025121807421028700_dgaf279-B5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01070-7","article-title":"Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A\/C gene","volume":"112","author":"Garg","year":"2002","journal-title":"Am J Med"},{"issue":"1","key":"2025121807421028700_dgaf279-B6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1399-0004.2009.01350.x","article-title":"Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A\/C mutations","volume":"78","author":"Subramanyam","year":"2010","journal-title":"Clin Genet"},{"issue":"12","key":"2025121807421028700_dgaf279-B7","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1210\/jc.2009-0472","article-title":"Atypical progeroid syndrome due to heterozygous missense LMNA mutations","volume":"94","author":"Garg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025121807421028700_dgaf279-B8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1210\/jc.2017-02078","article-title":"A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation","volume":"103","author":"Hussain","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025121807421028700_dgaf279-B9","doi-asserted-by":"crossref","first-page":"bvaa104","DOI":"10.1210\/jendso\/bvaa104","article-title":"Multisystem progeroid syndrome with lipodystrophy, cardiomyopathy, and nephropathy due to an LMNA p.R349W variant","volume":"4","author":"Hussain","year":"2020","journal-title":"J Endocr Soc"},{"issue":"12","key":"2025121807421028700_dgaf279-B10","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025121807421028700_dgaf279-B11","volume-title":"Endotext","author":"Akinci","year":"2000"},{"issue":"7","key":"2025121807421028700_dgaf279-B12","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","article-title":"Diagnostic value of anthropometric measurements for familial partial lipodystrophy, dunnigan variety","volume":"105","author":"Vasandani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025121807421028700_dgaf279-B13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/dbi24-0018","article-title":"Lipodystrophy prevalence, \u201clipodystrophy-like phenotypes,\u201d and diagnostic challenges","volume":"73","author":"Akinci","year":"2024","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"2025121807421028700_dgaf279-B14","first-page":"S20","article-title":"2. diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice C","year":"1 2024","journal-title":"Diabetes Care"},{"issue":"4","key":"2025121807421028700_dgaf279-B15","doi-asserted-by":"crossref","first-page":"III19","DOI":"10.1002\/clc.4960261505","article-title":"New features of the national cholesterol education program adult treatment panel III lipid-lowering guidelines","volume":"26","author":"Brewer","year":"2003","journal-title":"Clin Cardiol"},{"issue":"6","key":"2025121807421028700_dgaf279-B16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1040638720905833","article-title":"Guidelines for sanger sequencing and molecular assay monitoring","volume":"32","author":"Crossley","year":"2020","journal-title":"J Vet Diagn Invest"},{"key":"2025121807421028700_dgaf279-B17","author":"Anum"},{"issue":"3","key":"2025121807421028700_dgaf279-B18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1079\/BJN19780152","article-title":"Generalized equations for predicting body density of men","volume":"40","author":"Jackson","year":"1978","journal-title":"Br J Nutr"},{"issue":"3","key":"2025121807421028700_dgaf279-B19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1249\/00005768-198023000-00009","article-title":"Generalized equations for predicting body density of women","volume":"12","author":"Jackson","year":"1980","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"2025121807421028700_dgaf279-B20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2013.12.008","article-title":"LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response","volume":"40","author":"Chirico","year":"2014","journal-title":"Diabetes Metab"},{"issue":"3","key":"2025121807421028700_dgaf279-B21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-12-0268","article-title":"Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations","volume":"167","author":"Mory","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025121807421028700_dgaf279-B22","doi-asserted-by":"crossref","first-page":"bvac155","DOI":"10.1210\/jendso\/bvac155","article-title":"Phenotypic differences among familial partial lipodystrophy due to LMNA or PPARG variants","volume":"6","author":"Vasandani","year":"2022","journal-title":"J Endocr Soc"},{"issue":"5","key":"2025121807421028700_dgaf279-B23","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"2025121807421028700_dgaf279-B24","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/hmg\/ddi326","article-title":"Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition","volume":"14","author":"Glynn","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2025121807421028700_dgaf279-B25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1152\/physiolgenomics.00060.2005","article-title":"Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy","volume":"23","author":"Filesi","year":"2005","journal-title":"Physiol Genomics"},{"issue":"9","key":"2025121807421028700_dgaf279-B26","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1210\/jc.2004-2560","article-title":"A novel homozygous Ala529Val LMNA mutation in Turkish patients with mandibuloacral dysplasia","volume":"90","author":"Garg","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025121807421028700_dgaf279-B27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mus.20122","article-title":"Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A\/C gene mutations","volume":"30","author":"Muchir","year":"2004","journal-title":"Muscle Nerve"},{"issue":"3","key":"2025121807421028700_dgaf279-B28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41431-018-0294-0","article-title":"Assessment of fibroblast nuclear morphology aids interpretation of LMNA variants","volume":"27","author":"van Tienen","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2025121807421028700_dgaf279-B29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41525-021-00265-x","article-title":"Most myopathic lamin variants aggregate: a functional genomics approach for assessing variants of uncertain significance","volume":"6","author":"Anderson","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"3","key":"2025121807421028700_dgaf279-B30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025121807421028700_dgaf279-B31","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"2025121807421028700_dgaf279-B32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"2025121807421028700_dgaf279-B33","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"issue":"5","key":"2025121807421028700_dgaf279-B34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-12-0969","article-title":"Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial","volume":"168","author":"Ahmad","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025121807421028700_dgaf279-B35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","article-title":"Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study","volume":"20","author":"Foss-Freitas","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"6","key":"2025121807421028700_dgaf279-B36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"11","key":"2025121807421028700_dgaf279-B37","doi-asserted-by":"crossref","first-page":"e3617","DOI":"10.1210\/clinem\/dgaf173","article-title":"Efficacy and safety of obeticholic acid for treating hepatic steatosis in patients with familial partial lipodystrophy","volume":"110","author":"Garg","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf279\/63181612\/dgaf279.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/e214\/63181612\/dgaf279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/e214\/63181612\/dgaf279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:42:40Z","timestamp":1766061760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/1\/e214\/8131582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf279","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,5,14]]}}}